false
Catalog
2023 World Conference on Lung Cancer (Posters)
P2.09. Enhanced in Vivo Efficacy of Mobocertinib a ...
P2.09. Enhanced in Vivo Efficacy of Mobocertinib and Amivantamab Combination in EGFR ex20ins+ NSCLC PDX Models - PDF(Abstract)
Back to course
Pdf Summary
A study presented at the WCLC 2023 conference explored the efficacy of combining the drugs Mobocertinib and Amivantamab in treating EGFR ex20ins non-small cell lung cancer. Both drugs have received accelerated approval for single-agent use in this patient population. The researchers hypothesized that the combination therapy could further benefit these patients. <br /><br />The study tested the combined efficacy of Mobocertinib and Amivantamab in two human patient-derived xenograft (PDX) models of EGFR ex20ins NSCLC. The results showed that Mobocertinib alone had dose-dependent efficacy in inhibiting tumor growth, while Amivantamab alone had limited efficacy. However, when Amivantamab was combined with a suboptimal dose of Mobocertinib, there was enhanced benefit observed compared to Mobocertinib alone. <br /><br />Further molecular characterization with RNA and whole exome sequencing revealed specific genes and pathways associated with drug response and signaling in the tumors. The combination therapy activated pathways associated with cell-cycle checkpoints, MYC targets, and mTORC1, while downregulating apoptosis, IL2/STAT5, and inflammatory response pathways. <br /><br />Overall, the combination of Mobocertinib and Amivantamab showed synergetic efficacy in the PDX models. The study identified unique resistant molecular profiles to single-agent or combination treatments. Further testing of this combination therapy is warranted to potentially improve outcomes for patients with EGFR ex20ins NSCLC.
Asset Subtitle
Sampurna Chatterjee
Meta Tag
Speaker
Sampurna Chatterjee
Topic
Metastatic NSCLC: Targeted Therapy - EGFR/HER2
Keywords
WCLC 2023 conference
drug combination therapy
Mobocertinib
Amivantamab
EGFR ex20ins non-small cell lung cancer
accelerated approval
patient-derived xenograft (PDX) models
tumor growth inhibition
molecular characterization
synergetic efficacy
×
Please select your language
1
English